406939-92-2

Upstream product

• 295-37-4 1,4,8,11-Tetraazacyclotetradecane 
• 383-63-1 ethyl trifluoroacetate, 
• 76-05-1 trifluoroacetic acid 

Downstream Products

• 406939-93-3 1-(4,8-bis-(2,2,2-trifluoroacetyl)-11-{4-[4,8,11-tris-(2,2,2-trifluoroacetyl)-1,4,8,11-tetraazacyclotetradec-1-ylmethyl]-benzyl}-1,4,8,11-tetraazacyclotetradec-1-yl)-2,2,2-trifluoroethanone 
• 1246274-97-4 1-(3,5-bis(N-benzyl-5'-dimethylaminonaphthalene-1'-sulfonamido)benzyl)-1,4,8,11-tetraazacyclotetradecane 
• 1246274-96-3 1,4,8-tris(trifluoroacetyl)-11-(3,5-bis(N-benzyl-5'-dimethylaminonaphthalene-1'-sulfonamido)benzyl)1,4,8,11-tetraazacyclotetradecane 
• 1161392-63-7 C₃₀H₄₁F₉N₆O₄ 
• 110078-46-1 1-[4-(1,4,8,11-tetraazacyclotetradecan-1-ylmethyl)benzyl]-1,4,8,11-tetraazacyclotetradecane 
• 128495-29-4 1-(4-tolylsulfonyl)-1,4,8,11-tetraazacyclotetradecane 

Relevant academic research and scientific papers

Dramatically enhanced carbon acidity of the nitrobenzyl fragment in a nickel(II) scorpionate complex

(Chemical Equation Presented) The -CH2- group of the 2-nitrobenzyl pendant arm of the scorpionate complex I deprotonates in basic aqueous solution (pKa = 10.6), due to the coordination of the nitronate group to the nickel(II) center.

A new tris(phosphonomethyl) monoacetic acid cyclam derivative: Synthesis, acid-base and metal complexation studies

A new cyclam-based ligand, [4,8,11-tris(phosphonomethyl)-1,4,8,11- tetraazacyclotetradec-1-yl]acetic acid (H7te3p1a) was synthesised and characterised. The potentiometricand 31P NMR spectroscopic titrations of the complexes inan aqueous solution at an ionic strength of 0.10 or0.50 mol dm-3 in [N(CH3)4]NO3, respectively, indicated that the ligand is highly basic. The stepwise protonations were dominated by extensive proton relocations and were influenced by the intramolecular hydrogen bonds. The thermodynamic stability constants for the complexes formed by H7te3p1a in the presence of metal ions were determined by potentiometric titrations. The Cu2+ complexes exhibited very high stability, those of Zn2+, Cd2+, Pb 2+, La3+, Sm3+, Gd3+, Ho 3+ and Lu3+ presented high stability while that of Ca 2+ had lower stability, as expected. The ligand and its complexes behaviour is similar to that of the tetrakis(phosphonomethyl)cyclam derivative, H8tetp. The NMR spectroscopic studies of the Zn2+ and Cd2+ complexes pointed to the involvement of the three phosphonate moieties in the coordination of the latter ion, while several isomer species were generally present in solution for the Zn2+ complex. A major isomer was stabilised in solution upon heating. In this isomer only one of the methylphosphonate arms was coordinated to the metal centre and this isomer probably adopts a distorted square pyramidal geometry with the macrocyclic ring in the type I conformation.

Plerixafor crystal form D, plerixafor intermediate crystal form S and preparation methods and application thereof

The invention relates to a plerixafor crystal form D, a plerixafor intermediate crystal form S and preparation methods and application thereof. By preparing the plerixafor crystal form D, a plerixafor raw material medicine which is easier to store is obtained, the plerixafor crystallization process is simplified, and the plerixafor crystal form D is suitable for large-scale production. By preparing the plerixafor key intermediate crystal form S, the purification process of the intermediate is simplified, and the purity of the prepared plerixafor raw material medicine is improved.

COMPOSITIONS CONTAINING CANNABINOID ANALOG CONJUGATES AND METHODS OF USE

Provided here are compositions containing a conjugate of a label, a chelator, and a cannabinoid analog and methods for diagnosing, treating, or monitoring the progression of a cancer or a neurologic disorder using these compositions. Also provided here ar

Development and Evaluation of an 18F-Radiolabeled Monocyclam Derivative for Imaging CXCR4 Expression

In humans, C-X-C chemokine receptor type 4 (CXCR4) is a protein that is encoded by the CXCR4 gene and binds the ligand CXCL12 (also known as SDF-1). The CXCR4-CXCL12 interaction in cancer elicits biological activities that result in tumor progression and

Preparation method of plerixafor impurity

The invention discloses a preparation method of a plerixafor impurity and belongs to the field of medicine synthesis. By adopting the preparation method, a product with the purity reaching 99.16 percent can be obtained; a technology is simple in design and strong in operability and industrial production can be realized. The preparation method takes 1,4,8,11-tetraazacyclotetradecane as a raw material and realizes the synthesis of the plerixafor impurity through seven-step reaction; the plerixafor impurity prepared by the preparation method disclosed by the invention provides important evidencesfor carrying out scientific evaluation on quality, safety and efficiency of the plerixafor.

Cyclam-cored dendrimers appended with four dendrons of two different types: Intradendrimer energy transfer

We have synthesized two cyclam-cored dendrimers appended with dendrons of two different types by proper protection/deprotection of the cyclam unit. The resulting dendrimers contain six naphthyl and two dansyl units (N6D2) or two dansyl and six naphthyl un

64Cu-AMD3100-A novel imaging agent for targeting chemokine receptor CXCR4

CXCR4 is a chemokine receptor which has been shown to be exploited by various tumors for increased survival, invasion, and homing to target organs. We developed a one step radiosynthesis for labeling the CXCR4-specific antagonist AMD3100 with Cu-64 to pro

N-[3-[4-(2-methoxyphenyl) piperaziny-1-yl]propyl]cyclam: Synthesized as a potential 5-HT1A receptor ligand and labelled with 99mTc-nitrido core

This paper reports the synthesis of new potential 5-HT1A receptor ligand N-[3-[4-(2-methoxyphenyl)piperaziny-1-yl]propyl]cyclam (MPPC) and radiolabelling of it with 99mTc-nitrido core. The novel neutral complex 99mTcN-MPPC

Compositions and Methods for Cellular Imaging and Therapy

The present invention relates generally to the fields of chemistry and radionuclide imaging. More particularly, it concerns compositions, kits and methods for imaging and therapy involving N4 compounds and derivatives.